Omeros Corporation (OMER) Reports Fourth Quarter and Year-End 2013 Financial Results
3/14/2014 6:30:33 AM
SEATTLE, March 13, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and financial results for the fourth quarter and year ended December 31, 2013, which include:
•4Q 2013 net loss of $1.8 million, or $0.05 per share, and for the full year of 2013 a net loss of $39.8 million, or $1.39 per share
Help employers find you! Check out all the jobs and post your resume.
comments powered by